MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.

被引：0
|
作者：
Takita, H. [1 ,2 ]
Scotcher, D. [2 ]
Chinnadurai, R. [3 ]
Kalra, P. [3 ]
Galetin, A. [2 ]
机构：
[1] Asahi Kasei Pharma, Shizuoka, Japan
[2] Univ Manchester, Manchester, Lancs, England
[3] Salford Royal NHS Fdn Trust, Salford, Lancs, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-053
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [1] MECHANISTIC PBPK MODELING OF CREATININE-DRUG INTERACTIONS IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S85 - S85
  • [2] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF CREATININE-DRUG INTERACTION IN CHRONIC KIDNEY DISEASE POPULATION.
    Takita, H.
    Scotcher, D.
    Chinnadurai, R.
    Kalra, P.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S113 - S114
  • [3] Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population
    Takita, Hiroyuki
    Scotcher, Daniel
    Chinnadurai, Rajkumar
    Kalra, Philip A.
    Galetin, Aleksandra
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (12): : 695 - 706
  • [4] MECHANISTIC KIDNEY MODELS FOR CREATININE: RELEVANCE OF OCT2 TRANSPORT DRIVING FORCE TO PREDICTION OF CREATININE-DRUG INTERACTIONS
    Scotcher, Daniel
    Arya, Vikram
    Yang, Xinning
    Zhao, Ping
    Zhang, Lei K.
    Huang, Shiew-Mei
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S22 - S22
  • [5] Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions
    Scotcher, Daniel
    Arya, Vikram
    Yang Xinning
    Zhao Ping
    Zhang Lei
    Huang Shiew-Mei
    Rostami-Hodjegan, Amin
    Galetin, Aleksandra
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (05): : 282 - 293
  • [6] Transporters affecting biochemical test results: Creatinine-drug interactions
    Chu, X.
    Bleasby, K.
    Chan, G. H.
    Nunes, I.
    Evers, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) : 437 - 440
  • [7] Costs of chronic kidney disease (CKD) in a large HMO population.
    Smith, D
    Gullion, C
    Nichols, G
    Keith, D
    Brown, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 618A - 619A
  • [8] Mortality of chronic kidney disease (CKD) in a large HMO population.
    Keith, D
    Nichols, G
    Gullion, C
    Brown, J
    Smith, D
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 620A - 620A
  • [9] Chronic kidney disease - an epidemic of the aging population. How to establish a boundary between physiological aging and chronic kidney disease?
    Wikarek, Tomasz
    Chudek, Jerzy
    [J]. FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2010, 12 (02): : 496 - 500
  • [10] APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING FOR PREDICTION OF THE DRUG-DRUG INTERACTION (DDI) BETWEEN PAROXETINE AND TERBINAFINE IN A JAPANESE POPULATION.
    Yeo, K. Rowland
    Barter, Z.
    Almond, L.
    Rostami-Hodjegan, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S119 - S120
12345